Hims & Hers Health (NYSE:HIMS) Rating Lowered to Hold at Wall Street Zen

Hims & Hers Health (NYSE:HIMS) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also commented on HIMS. UBS Group reiterated a “mixed” rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Truist Financial cut their target price on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating for the company in a research note on Thursday, April 10th. Bank of America lifted their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research note on Tuesday, April 29th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average price target of $38.00.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $56.44 on Friday. Hims & Hers Health has a 52-week low of $13.47 and a 52-week high of $72.98. The stock has a fifty day moving average of $42.23 and a 200 day moving average of $37.33. The firm has a market capitalization of $12.63 billion, a price-to-earnings ratio of 128.28 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter last year, the company posted $0.05 EPS. Equities analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the transaction, the chief executive officer now directly owns 173,655 shares of the company’s stock, valued at approximately $5,900,796.90. The trade was a 42.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the company’s stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $52.98, for a total transaction of $613,561.38. Following the completion of the transaction, the chief financial officer now owns 39,153 shares of the company’s stock, valued at $2,074,325.94. This trade represents a 22.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 617,367 shares of company stock valued at $25,227,888 over the last ninety days. 13.71% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Smartleaf Asset Management LLC raised its stake in Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after buying an additional 227 shares in the last quarter. Allworth Financial LP raised its position in shares of Hims & Hers Health by 20.0% in the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock worth $56,000 after acquiring an additional 334 shares in the last quarter. Signaturefd LLC raised its position in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after acquiring an additional 388 shares in the last quarter. SlateStone Wealth LLC lifted its stake in shares of Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after purchasing an additional 413 shares during the period. Finally, Kilter Group LLC boosted its position in shares of Hims & Hers Health by 1.0% during the first quarter. Kilter Group LLC now owns 43,989 shares of the company’s stock valued at $1,300,000 after purchasing an additional 450 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.